Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Cocrystal Pharma, Inc. (COCP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Quarterly results
Docs: "COCRYSTAL PHARMA, INC. CONSOLIDATED BALANCE SHEETS"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/24/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs"
05/12/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/24/2023 8-K Quarterly results
04/14/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/10/2023 SC 13G/A SABBY MANAGEMENT, LLC reports a 5.2% stake in Cocrystal Pharma, Inc.
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/26/2022 8-K Quarterly results
10/03/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 8-K Quarterly results
07/29/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/20/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
04/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/01/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/23/2022 10-K Annual Report for the period ended December 31, 2021
03/23/2022 8-K Quarterly results
Docs: "Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones"
02/10/2022 SC 13G/A RENAISSANCE TECHNOLOGIES LLC reports a 2% stake in COCRYSTAL PHARMA, INC.
01/03/2022 SC 13G/A SABBY MANAGEMENT, LLC reports a 5.9% stake in Cocrystal Pharma, Inc.
12/22/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Cocrystal Pharma’ s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant"
11/19/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
11/15/2021 10-Q Quarterly Report for the period ended September 30, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy